Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Sees Significant Decrease in Short Interest

Inhibitor Therapeutics, Inc. (OTCMKTS:INTIGet Rating) saw a large drop in short interest in April. As of April 15th, there was short interest totalling 100 shares, a drop of 50.0% from the March 31st total of 200 shares. Based on an average daily volume of 5,700 shares, the short-interest ratio is presently 0.0 days.

Shares of OTCMKTS:INTI opened at $0.14 on Friday. Inhibitor Therapeutics has a 52 week low of $0.06 and a 52 week high of $0.35. The firm’s fifty day moving average is $0.14 and its 200-day moving average is $0.15.

About Inhibitor Therapeutics (Get Rating)

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.

Featured Articles

Receive News & Ratings for Inhibitor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibitor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.